The medtech industry has expressed concern over draft proposals from the US Food and Drug Administration for the agency to disclose to the public information on medical devices and drugs that have not yet been approved1.
Disclosing information on pending device applications – ie pre-market approval applications and pre-market notifications or 510(k)s – are a special concern for medtech companies because patents provide less protection for devices and diagnostics than they do for drugs or biologics, claims US industry association AdvaMed...
Please login to read the full article.
